Interleukin 34: a new modulator of human and experimental inflammatory bowel disease.

Treatment with celastrol, an inhibitor of NF-κB, resulted in 80% inhibition of TNF-α-induced IL34 , and treatment with the inhibitor of the downstream IKKβ [IκB (inhibitor of NF-κB) kinase β] resulted in 25% inhibition of TNF-α-induced IL34 , which did not reach statistical significance.

also in 111,027 other papers